The U.S. Department of Justice has intensified False Claims Act enforcement in the wound care industry, targeting allegedly medically unnecessary skin substitutes, improper billing practices, and kickback arrangements. With billion-dollar settlements and a record-breaking $6.8 billion in FCA recoveries for fiscal year 2025, federal scrutiny of manufacturers, distributors, and healthcare providers continues to escalate. How are recent Medicare reimbursement changes and regulatory concerns reshaping complianc
United StatesGovernment, Public Sector
Quick Summary
DOJ continues to prioritize False Claims Act enforcement in the wound care industry, increasing scrutiny of allegedly medically unnecessary skin substitutes, improper billing, and kickback arrangements. Recent billion-dollar and multimillion-dollar enforcement actions, public statements, and the 2026 National Health Care Fraud Takedown reflect sustained federal focus on manufacturers, distributors, and healthcare providers. Amid growing regulatory concern over rising spending on skin substitute products, CMS’s Medicare reimbursement changes reshape payment incentives and create new compliance considerations. Companies should strengthen documentation, billing and coding practices, compliance programs, and training to reduce healthcare fraud enforcement risk under the False Claims Act and Anti-Kickback Statute. |
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source
